Exploring 5-year changes in general and skin health-related quality of life in psoriatic arthritis patients
Abstract Psoriatic arthritis (PsA) carries a severe disease burden, often leading to deterioration of health-related quality of life (HRQoL). Different comorbidities that are relatively prevalent in PsA are also responsible for compromised HRQoL. To assess real-world data of a 5-year follow-up cohort of PsA patients, focusing on changes in general HRQoL, skin HRQoL, and comorbidities. In this prospective observational study, 114 outpatients diagnosed with PsA were examined at baseline and after 5 years. Data collection included demographics, clinical disease activity measures, and patient-reported outcome measures (PROMs). General HRQoL was assessed with a 15D instrument, and skin HRQoL was assessed with the Dermatology Life Quality Index (DLQI). During the 5-year follow-up, no significant deterioration in HRQoL assessed by 15D (23.53 vs. 23.08, p = 0.85) and DLQI (3.48 vs. 2.68, p = 0.07) was observed. There was no observed decline in other PROMs. The mean total number of comorbidities increased (1.13 vs. 1.39, p < 0.01). A significant improvement in disease activity measures, including 66/68 swollen/tender joint count, Disease Activity Index for Psoriatic Arthritis (all p < 0.01), and Psoriatic Arthritis Severity Index (p = 0.04) was seen. A higher proportion of patients at 5 years were treated with b/tsDMARDs (37.7% vs. 46.5%, p = 0.03). Despite an increased number of comorbidities over 5 years, our PsA cohort showed no decline in HRQoL. This can be attributed to the widespread adoption of modern treatments, leading to improved disease control and the preservation of baseline HRQoL..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Rheumatology international - 44(2024), 4 vom: 06. Feb., Seite 675-685 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wilk, Mateusz [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Biological therapy |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00296-024-05536-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055023592 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055023592 | ||
| 003 | DE-627 | ||
| 005 | 20240306064642.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00296-024-05536-1 |2 doi | |
| 035 | |a (DE-627)SPR055023592 | ||
| 035 | |a (SPR)s00296-024-05536-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wilk, Mateusz |e verfasserin |0 (orcid)0000-0001-7967-0880 |4 aut | |
| 245 | 1 | 0 | |a Exploring 5-year changes in general and skin health-related quality of life in psoriatic arthritis patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Psoriatic arthritis (PsA) carries a severe disease burden, often leading to deterioration of health-related quality of life (HRQoL). Different comorbidities that are relatively prevalent in PsA are also responsible for compromised HRQoL. To assess real-world data of a 5-year follow-up cohort of PsA patients, focusing on changes in general HRQoL, skin HRQoL, and comorbidities. In this prospective observational study, 114 outpatients diagnosed with PsA were examined at baseline and after 5 years. Data collection included demographics, clinical disease activity measures, and patient-reported outcome measures (PROMs). General HRQoL was assessed with a 15D instrument, and skin HRQoL was assessed with the Dermatology Life Quality Index (DLQI). During the 5-year follow-up, no significant deterioration in HRQoL assessed by 15D (23.53 vs. 23.08, p = 0.85) and DLQI (3.48 vs. 2.68, p = 0.07) was observed. There was no observed decline in other PROMs. The mean total number of comorbidities increased (1.13 vs. 1.39, p < 0.01). A significant improvement in disease activity measures, including 66/68 swollen/tender joint count, Disease Activity Index for Psoriatic Arthritis (all p < 0.01), and Psoriatic Arthritis Severity Index (p = 0.04) was seen. A higher proportion of patients at 5 years were treated with b/tsDMARDs (37.7% vs. 46.5%, p = 0.03). Despite an increased number of comorbidities over 5 years, our PsA cohort showed no decline in HRQoL. This can be attributed to the widespread adoption of modern treatments, leading to improved disease control and the preservation of baseline HRQoL. | ||
| 650 | 4 | |a Quality of life |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Psoriatic arthritis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Psoriasis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Comorbidities |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Follow-up study |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Biological therapy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Michelsen, Brigitte |0 (orcid)0000-0003-0103-2840 |4 aut | |
| 700 | 1 | |a Łosińska, Katarzyna |0 (orcid)0000-0003-2801-6584 |4 aut | |
| 700 | 1 | |a Kavanaugh, Arthur |0 (orcid)0000-0001-6942-5830 |4 aut | |
| 700 | 1 | |a Korkosz, Mariusz |0 (orcid)0000-0002-1749-9739 |4 aut | |
| 700 | 1 | |a Haugeberg, Glenn |0 (orcid)0000-0002-9279-5191 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d Berlin : Springer, 1981 |g 44(2024), 4 vom: 06. Feb., Seite 675-685 |w (DE-627)SPR00382473X |w (DE-600)1464208-6 |x 1437-160X |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:4 |g day:06 |g month:02 |g pages:675-685 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00296-024-05536-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 4 |b 06 |c 02 |h 675-685 | ||